Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium stearylfumarate; hypromellose; pregelatinised maize starch; iron oxide yellow - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension.,post mi heart failure,prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - tablet - excipient ingredients: sodium stearylfumarate; pregelatinised maize starch; iron oxide yellow; microcrystalline cellulose; hypromellose - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension.,post mi heart failure,prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 2.5 mg - tablet - excipient ingredients: hypromellose; microcrystalline cellulose; pregelatinised maize starch; sodium stearylfumarate; iron oxide red - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension.,post mi heart failure,prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease.,for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - modafinil, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; microcrystalline cellulose; ethanol; purified water; mannitol; magnesium stearate; crospovidone - - to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy; - to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate; - as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - armodafinil, quantity: 150 mg - tablet, uncoated - excipient ingredients: povidone; microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; lactose monohydrate; magnesium stearate - ?to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy,?to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate ,?as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - armodafinil, quantity: 250 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; lactose monohydrate; povidone; pregelatinised maize starch; magnesium stearate - ?to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy,?to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where nonpharmacological interventions are unsuccessful or inappropriate,?as an adjunct to continuous positive airways pressure (cpap) in obstructive sleep apnoea/hypopnoea syndrome in order to improve wakefulness.

Australia - English - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 300 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 150 mg - tablet - excipient ingredients: povidone; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 75 mg - tablet - excipient ingredients: croscarmellose sodium; lactose monohydrate; povidone; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 75 mg - tablet, film coated - excipient ingredients: lactose monohydrate; croscarmellose sodium; povidone; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan is indicated for the following: for the treatment of hypertension. for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (equal to or greater than 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.